Mismatch Repair-Deficient Colorectal Tumors Responded to Pembrolizumab

In this video, Dung T. Le, MD, discusses a phase II study that found that mismatch repair–deficient colorectal tumors were highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.

In this video, Dr. Le discusses a phase II study that found that colorectal tumors lacking the ability to repair DNA-or mismatch repair–deficient tumors-were highly responsive to checkpoint blockade with the anti–programmed death 1 (PD-1) drug pembrolizumab. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. Read our conference report of this study.